7-fluoro-1,3,3-trimethylindolin-2-one | 872141-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-fluoro-1,3,3-trimethylindolin-2-one
• 英文别名: 7-fluoro-1,3,3-trimethylindol-2-one
• CAS: 872141-33-8
• 化学式: C₁₁H₁₂FNO
• 分子量: 193.221
• InChiKey: YZGOOMUYZSUXDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-fluoro-1,3,3-trimethylindolin-2-one 在 溴 、 sodium acetate 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以82%的产率得到5-bromo-7-fluoro-1,3,3-trimethyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Progesterone receptor antagonists, contraceptive regimens, and kits

  摘要：

  提供了一种避孕方法，涉及在没有孕激素、雌激素或其他类固醇化合物的情况下，连续给予21至27天的一种或多种PR拮抗剂，然后在没有任何活性药物的情况下进行1至7天。还描述了一个在药学上有用的工具包，以便实施这种方案的交付。

  公开号：

  US20060009509A1
• 作为产物：
  描述：

  N-甲基-2-氟苯胺 在 [bis(2-methylallyl)cycloocta-1,5-diene]ruthenium(II) 、 溶剂黄146 、 三乙胺 、 1,3-双(2,6-二异丙基苯基)咪唑-2-烯 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 7-fluoro-1,3,3-trimethylindolin-2-one
  参考文献：
  名称：

  钌催化的分子内烯烃加氢芳基化的束缚指导基团策略

  摘要：

  我们报道了一种用于N杂环合成的新催化剂设计，该催化剂利用烯烃系酰胺部分作为芳族CH活化的导向基团。该束缚指导基团策略在钌催化的分子内烯烃与N-芳基丙烯酰胺的氢芳基化反应中形成羟吲哚产物。

  DOI：

  10.1039/c7cc08704g

文献信息

• [EN] INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS INDOLIN-2-ONE OU PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014202493A1

  公开（公告）日：2014-12-24

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, dimethylamino, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, CH(OH)CF3, (CH2)o-lower alkoxy, cycloalkyl optionally substituted by CF3, or heterocycloalkyl optionally substituted by lower alkyl; R2 is hydrogen, lower alkyl, (CH2)o-cycloalkyl, (CH2)o-O-cycloalkyl, (CH2)o-lower alkoxy, CH2)o-lower alkoxy substituted by halogen, (CH2)o-heterocycloalkyl optionally substituted by lower alkyl, (CH2)o-S(O)2-cycloalkyl, lower alkyl substituted by one or two hydroxy, lower alkyl substituted by one or two lower alkoxy, (CH2)o-S(O)2-lower alkyl, lower alkyl substituted by halogen or CH2CH(OH)CF3; R3 is halogen or lower alkyl; X is CH or N; X1 is CH or N; n is 1 or 2; o is 0, 1, 2 or 3; m is 0, 1 or 2; and the dotted line is a bond or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及通式（I）中的2-氧代-2,3-二氢吲哚，其中Ar是一个杂环烃基，含有一个、两个或三个杂原子，选自N、S或O；R1是氢、低碳基、卤素、氨基、二甲胺基、氰基、被卤素取代的低碳基、被羟基取代的低碳基、CH(OH)CF3、（CH2）o-低碳醚、环烷基（可选地被CF3取代）、或杂环烷基（可选地被低碳基取代）；R2是氢、低碳基、（CH2）o-环烷基、（CH2）o-O-环烷基、（CH2）o-低碳醚、被卤素取代的（CH2）o-低碳醚、（CH2）o-杂环烷基（可选地被低碳基取代）、（CH2）o-S(O)2-环烷基、被一个或两个羟基取代的低碳基、被一个或两个低碳醚取代的低碳基、（CH2）o-S(O)2-低碳基、被卤素或CH2CH(OH)CF3取代的低碳基；R3是卤素或低碳基；X是CH或N；X1是CH或N；n是1或2；o是0、1、2或3；m是0、1或2；虚线是键或非键；以及其在药学上可接受的盐、消旋混合物、或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗某些中枢神经系统障碍，包括精神病（阳性和阴性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重性抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎的抗炎作用和平衡问题。
• [EN] 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] 2-OXO-2,3-DIHYDRO-INDOLES DESTINÉS AU TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014040969A1

  公开（公告）日：2014-03-20

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N1) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N2) is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or halogen; n is 1 or 2; if n is 2, R1 may be the same or not; R2/R2' are independently from each other lower alkyl, or form together with the carbon atom to which they are attached a C3-6-cycloalkyl ring; R3 is lower alkyl, C3-6-cycloalkyl, CH2-C3-6-cycloalkyl, C3-6-cycloalkyl wherein one ring-carbon atom is replaced by -O-, (CH2)3-O-C3-6-cycloalkyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, (CH2)3-S(O)2-C3-6-cycloalkyl or (CH2)2-S(O)2-lower alkyl; R4 is hydrogen, halogen or lower alkyl; m is 1 or 2; if m is 2, R4 may be the same or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

  本发明涉及一般式(I)的2-氧代-2,3-二氢吲哚，其中（N1）是苯基或杂环芳基，选择自吡啶基、嘧啶基、咪唑基、异噁唑基或吡唑基；（N2）是苯基或吡啶基，其中吡啶基中的N原子可以在所有自由位置上；R1是氢、低碳基、被卤素取代的低碳基、低烷氧基或卤素；n为1或2；若n为2，则R1可以相同也可以不同；R2/R2'彼此独立地为低碳基，或与它们连接的碳原子一起形成一个C3-6环烷基环；R3是低碳基、C3-6环烷基、CH2-C3-6环烷基、C3-6环烷基其中一个环碳原子被-O-取代、（CH2）3-O-C3-6环烷基、被羟基取代的低碳基、被卤素取代的低碳基、（CH2）3-S(O)2-C3-6环烷基或（CH2）2-S(O)2-低碳基；R4是氢、卤素或低碳基；m为1或2；若m为2，则R4可以相同也可以不同；以及其药学上可接受的盐、消旋混合物、或其对应的对映体和/或光学异构体和/或立体异构体。
• [EN] INDOLIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017076842A1

  公开（公告）日：2017-05-11

  The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

  本发明涉及一般式(I)的吲哚啉-2-酮衍生物，其中取代基如权利要求书中所定义。这些化合物可用于治疗与精神分裂症的阳性（精神病）和阴性症状、物质滥用、酒精和药物成瘾、强迫症障碍、认知障碍、双相障碍、情绪障碍、重度抑郁症、治疗抗性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合症、僵硬、炎症性疾病、哮喘、亨廷顿病、注意力缺陷多动障碍、肌萎缩侧索硬化、关节炎、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病以及平衡问题、癫痫和伴有癫痫的神经发育障碍相关的中枢神经系统疾病的治疗。
• [EN] PROGESTERONE RECEPTOR ANTAGONIST CONTRACEPTIVE REGIMENS AND KITS<br/>[FR] REGIMES ET KITS CONTRACEPTIFS D'ANTAGONISTE DE RECEPTEUR DE PROGESTERONE
  申请人：WYETH CORP

  公开号：WO2006017075A1

  公开（公告）日：2006-02-16

  A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.

  提供了一种避孕方法，其中在没有孕激素、雌激素或其他类固醇化合物的情况下，连续给予21至27天的一个或多个PR拮抗剂，随后停药1至7天。还描述了一个药用工具箱，以便于执行这种治疗方案。
• Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
  申请人：Fensome Andrew

  公开号：US20060030717A1

  公开（公告）日：2006-02-09

  Pyrrole-oxindole derivatives useful as progesterone receptor antagonists, and methods for preparing the same, are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.

  提供了用作孕激素受体拮抗剂的吡咯-氧化吲哚衍生物以及其制备方法。还描述了含有这些衍生物的药物组合物，以及在避孕和激素相关疾病中使用它们的用途。